Harsukh Parma, VP at Roche to Speak at 8th Modern Drug Summit Oct 24-26, 2012

Philadelphia, PA (PressExposure) September 26, 2012 -- Harsukh Parmar, Vice President & Global Head of Translational & Experimental Medicine, Inflammation at Roche will give a plenary keynote presentation on "Innovation Through Cutting Edge Translational Medicine & Virtual Pharma Model to Transform R&D Productivity" at the 8th Modern Drug Discovery & Development Summit taking place on October 24-26, 2012 in Philadelphia, PA

R & D productivity remains poor despite continual increase in R & D budgets. Innovation has often become stifled in large companies by huge demands on unrealistic target product profiles (TPP's), self-perpetuating huge bureaucracies, inadequate human target validation, excessive spend on easily tractable targets, incapability of delivering differentiated products, and poor leadership in decision making at all phases of R & D. These deficiencies lead to large excessive spend of R & D budgets on projects which get into human clinical trials but which have no future and which have no chance of delivering the agreed TPP's wanted by the strategic marketing organizations. Currently marketed products, which are now becoming generic, continue to pose high hurdles on efficacy and safety and benchmarking against these products is often poor in early stages of discovery and early development. Failure on efficacy grounds in Phase IIb and Phase III is still very common and is unacceptable from both an ethical and R & D budget perspective. This model needs to change. True globalization, better "human target validation", stronger input from translational medicine, excellence in visionary leadership who truly understand R & D and transformation into a virtual pharma model are all viable options to address some of these productivity challenges.

Dr. Harsukh joined Pfizer Central Research in 1994 in the Dept of Experimental Medicine as Clinical Project Manager/Associate Director and worked on various anti-bacterial, anti-fungal, cardiovascular and oncology projects. Later he joined Roche Global Drug Development as Global Clinical Science Leader, Director of Oncology and worked on various projects in oncology, virology, asthma and allergy. From 1998-2011 he was appointed at AstraZeneca R & D with increasing levels of responsibility to the role Global Head of Early Clinical Development, Respiratory & Inflammation Therapeutic Area, AstraZeneca, spread across 4 global R & D sites. He also chaired and lead the cross-functional Translational Medicine Leadership Team comprising of both discovery and development functions within AstraZeneca and Medimmune. He served for 7 years on the AZ global human exposures limit committee, responsible for transition of all new NME's into man, women of child bearing age and children. In Sept 2011, he was appointed VP & Global Head of Translational & Experimental Medicine, Inflammation DTA, Hoffman La Roche, USA.

GTC's 8th Modern Drug Discovery and Development Summit features a plenary keynote session followed by five parallel tracks:

9th Stem Cell Research and Therapeutics Conference

7th Assay and Drug Discovery Technologies Conference

4th Translational Medicine Conference

3rd Pharmacokinetics and Pharmacodynamics Conference

Biotechnology Transfer and Commercialization Conference

For more information, please visit http://www.gtcbio.com

About GTC Conference

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source: http://PressExposure.com/PR/GTC_Conference.html

Press Release Submitted On: September 26, 2012 at 9:55 pm
This article has been viewed 66983 time(s).